Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
ROCKET PHARMACEUTICALS, INC. terminated Prior Sales Agreement with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC (effective 2026-03-10).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC
- Effective
- 2026-03-10
Exact text from the filing
Upon entry into the Sales Agreement, the Company terminated its prior “at-the-market” sales agreement with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC, dated February 28, 2022, (the “Prior Sales Agreement”), as amended by Amendment No. 1 to the Prior Sales Agreement, dated as of September 12, 2023 (“Amendment No. 1”), pursuant to which the Company could offer and sell, from time to time through Cowen and Company, LLC, as its agent, shares of the Company’s common stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
ROCKET PHARMACEUTICALS, INC. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at $100,000,000 (effective 2026-03-10).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Cantor Fitzgerald & Co.
- Value
- $100,000,000
- Effective
- 2026-03-10
Exact text from the filing
On March 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Sales Agent”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $100,000,000 (the “Shares”), through the Sales Agent.
View on SEC.gov